Dynavax Technologies Co. (NASDAQ:DVAX) Shares Sold by Bank of America Corp DE

Bank of America Corp DE reduced its position in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 15.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 699,026 shares of the biopharmaceutical company's stock after selling 124,301 shares during the quarter. Bank of America Corp DE owned about 0.53% of Dynavax Technologies worth $8,927,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of DVAX. SG Americas Securities LLC purchased a new position in shares of Dynavax Technologies in the 4th quarter valued at $990,000. Palumbo Wealth Management LLC purchased a new position in Dynavax Technologies during the 4th quarter worth $275,000. Barclays PLC grew its stake in Dynavax Technologies by 137.4% during the 3rd quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company's stock worth $3,371,000 after buying an additional 175,118 shares during the last quarter. Schonfeld Strategic Advisors LLC grew its stake in Dynavax Technologies by 97.6% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 310,430 shares of the biopharmaceutical company's stock worth $3,964,000 after buying an additional 153,302 shares during the last quarter. Finally, First Trust Advisors LP purchased a new position in Dynavax Technologies during the 4th quarter worth $847,000. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

DVAX has been the topic of several research analyst reports. HC Wainwright restated a "buy" rating and set a $31.00 target price on shares of Dynavax Technologies in a research note on Friday, February 21st. William Blair restated an "outperform" rating on shares of Dynavax Technologies in a research note on Friday, February 21st. JMP Securities dropped their price target on Dynavax Technologies from $33.00 to $31.00 and set a "market outperform" rating on the stock in a research note on Wednesday, May 7th. Wall Street Zen downgraded Dynavax Technologies from a "buy" rating to a "hold" rating in a research note on Tuesday, May 6th. Finally, The Goldman Sachs Group dropped their price target on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating on the stock in a research note on Thursday, April 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $24.00.

Dynavax Technologies Stock Performance

Shares of DVAX stock traded down $0.22 on Wednesday, hitting $9.57. The company had a trading volume of 1,160,973 shares, compared to its average volume of 2,215,443. The firm has a market cap of $1.15 billion, a P/E ratio of 53.25 and a beta of 1.26. The company has a 50-day moving average price of $11.25 and a 200-day moving average price of $12.40. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. Dynavax Technologies Co. has a twelve month low of $9.22 and a twelve month high of $14.63.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.14). The company had revenue of $68.16 million during the quarter, compared to analyst estimates of $70.01 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. As a group, equities research analysts predict that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.